Astex Pharmaceuticals

Astex Pharmaceuticals

Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.

Telephone: +44 (0)1223 226 200
Address: 436 Cambridge Science Park, Milton Road, Cambridge
Postcode: CB4 0QA
Country: United Kingdom
Website: http://www.astx.com
Membership type:Corporate 51+ (£1,000+VAT pa)

Innovative Discovery
Enhanced Opportunities

Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.

Oncology Focused

We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.

Financially Strong

We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver future product milestones plus royalties.

Harren Jhoti PhD

Astex’s Harren Jhoti made Fellow of the Royal Society

Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti PhD, co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been elected a Fellow of the Royal Society in recognition of his outstanding contribution to drug discovery research and science in general.

9 May 2018Read in full

Astex continues to deliver in oncology

Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced that its pharmaceutical collaborator, Janssen Pharmaceutica NV has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.

16 March 2018Read in full

Dementia Consortium signs new pharma partner Astex Pharmaceuticals

The Dementia Consortium, a unique charity-private partnership, today announced Astex Pharmaceuticals as a new member.

12 October 2015Read in full

Cancer Research and Astex join forces to trial potential new cancer treatments

Cancer Research UK's Drug Development Office (DDO) has announced that Astex Pharmaceuticals will join its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance with an aim to develop new cancer treatments.

16 May 2014Read in full